Prospective randomized trial comparing relapse rates in dogs with steroid-responsive meningitis-arteritis treated with a 6-week or 6-month prednisolone protocol
Journal of Veterinary Internal Medicine · 2024
DOI: 10.1111/jvim.17130 ↗At a glance
Randomisierte kontrollierte Studie in Journal of Veterinary Internal Medicine, 2024. Written by Jeremy H Rose and 10 co-authors. Institution: Lumbry Park Veterinary Specialists, CVS Group plc, Alton, United Kingdom. Major MEDLINE topics: Prednisolone, Dog Diseases, Recurrence, Arteritis. Cited 6 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Traditionally, 6-month courses of prednisolone are used to treat steroid-responsive meningitis-arteritis (SRMA), but this medication is associated with adverse effects that can lead to poor quality of life. Hypothesis/Objectives Resolution of clinical signs and rate of relapse of SRMA would not be significantly different between a 6-month prednisolone protocol and a 6-week protocol. Animals Forty-four hospital cases from multiple referral centers in the United Kingdom (2015-2019). Twenty of 44 were treated with the 6-month protocol and 24/44 with the 6-week protocol.
Methods
Prospective, randomized trial with 12-month follow-up. The same prednisolone protocol reinitiated in the event of relapse. Analysis of relapses with binary logistic and Poisson regression modeling.
Results
All cases responded to their treatment protocol. Relapses occurred in 6/20 (30%) of the 6-month protocol and 9/24 (38%) of the 6-week protocol. There was no statistical difference in the incidence risk of at least 1 relapse between the 2 groups (odds ratio = 1.40; 95% confidence interval [CI], 0.40-4.96, P = 0.60). Among the 15 dogs that relapsed, 10/15 (67%) relapsed once, 3/15 (20%) relapsed twice, and 2/15 (13%) relapsed 3 times. No statistical difference was detected in the incidence rate ratio (IRR) of total relapse events between the 2 groups (IRR = 1.46; 95% CI, 0.61-3.48; P = 0.40). Conclusions and Clinical Importance “Short” 6-week prednisolone protocols could be used to treat SRMA, thereby presumably reducing the duration and severity of prednisolone's adverse effects.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Lumbry Park Veterinary Specialists, CVS Group plc, Alton, United Kingdom.
- Cave Veterinary Specialists, Linnaeus group, Wellington, United Kingdom.
- College of Veterinary Medicine, North Carolina State University, Raleigh, USA.
- Blaise Referrals, IVC Evidensia Referrals, Birmingham, United Kingdom.
- CVS Group plc, Diss, United Kingdom.
- Paragon Veterinary Referrals, Linnaeus group, Wakefield, United Kingdom.
ORCID profiles: Jeremy H Rose, Anna Tauro, Thomas R Harcourt-Brown
Cite
APA
Rose, J. H., Driver, C. J., Arrol, L., Cardy, T. J. A., Tabanez, J., Tauro, A., Fernandes, R., Schofield, I., Adamantos, S., Granger, N., & Harcourt-Brown, T. R. (2024). Prospective randomized trial comparing relapse rates in dogs with steroid-responsive meningitis-arteritis treated with a 6-week or 6-month prednisolone protocol. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17130
Vancouver
Rose JH, Driver CJ, Arrol L, Cardy TJA, Tabanez J, Tauro A, et al. Prospective randomized trial comparing relapse rates in dogs with steroid-responsive meningitis-arteritis treated with a 6-week or 6-month prednisolone protocol. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17130
BibTeX
@article{Rose2024,
author = {Rose, Jeremy H and Driver, Colin J and Arrol, Lorna and Cardy, Thomas J A and Tabanez, Joana and Tauro, Anna and Fernandes, Ricardo and Schofield, Imogen and Adamantos, Sophie and Granger, Nicolas and Harcourt-Brown, Thomas R},
title = {Prospective randomized trial comparing relapse rates in dogs with steroid-responsive meningitis-arteritis treated with a 6-week or 6-month prednisolone protocol},
journal = {Journal of Veterinary Internal Medicine},
year = {2024},
doi = {10.1111/jvim.17130}
}
EUVIMED